Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | -5.76% | |
| Gapped Down | Weakness | -5.76% | |
| Lower Bollinger Band Touch | Weakness | -5.76% | |
| Fell Below 20 DMA | Bearish | -15.49% | |
| Fell Below 50 DMA | Bearish | -15.49% | |
| Inside Day | Range Contraction | -15.49% | |
| Gapped Down | Weakness | -15.49% | |
| Crossed Above 20 DMA | Bullish | -23.02% | |
| Crossed Above 50 DMA | Bullish | -23.02% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -23.02% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Down 5% | about 6 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Lower Bollinger Band | about 6 hours ago |
| Fell Below Previous Day's Low | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/14/2024
Virpax Pharmaceuticals, Inc. Description
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Sciences Drugs Pain Euphoriants Opioids Influenza Pain Management Drug Delivery Analgesics Morphinans Post Traumatic Stress Disorder Drug Delivery Systems Heroin Bupivacaine Morphine Nasal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.774 |
| 52 Week Low | 2.402 |
| Average Volume | 27,593 |
| 200-Day Moving Average | 5.87 |
| 50-Day Moving Average | 3.75 |
| 20-Day Moving Average | 3.79 |
| 10-Day Moving Average | 3.58 |
| Average True Range | 0.39 |
| RSI (14) | 41.86 |
| ADX | 21.2 |
| +DI | 20.37 |
| -DI | 26.04 |
| Chandelier Exit (Long, 3 ATRs) | 3.51 |
| Chandelier Exit (Short, 3 ATRs) | 4.41 |
| Upper Bollinger Bands | 4.35 |
| Lower Bollinger Band | 3.23 |
| Percent B (%b) | 0.06 |
| BandWidth | 29.50 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0412 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.93 | ||||
| Resistance 3 (R3) | 3.97 | 3.81 | 3.82 | ||
| Resistance 2 (R2) | 3.81 | 3.65 | 3.79 | 3.79 | |
| Resistance 1 (R1) | 3.55 | 3.55 | 3.47 | 3.51 | 3.75 |
| Pivot Point | 3.39 | 3.39 | 3.35 | 3.37 | 3.39 |
| Support 1 (S1) | 3.14 | 3.23 | 3.06 | 3.09 | 2.85 |
| Support 2 (S2) | 2.98 | 3.13 | 2.95 | 2.81 | |
| Support 3 (S3) | 2.72 | 2.98 | 2.78 | ||
| Support 4 (S4) | 2.67 |
